On the one hand, MCT1 and MCT2 seem important in the maintenance of localized disease, whereas MCT4 is related with an aggressive phenotype, leading to the idea that different MCTs should be targeted across PCa disease progression. The gene discussed is SLC16A1; the disease is posterior cortical atrophy.